title: Synergism between RIZ1 gene therapy and paclitaxel in SiHa cervical cancer cells.
abstract: RIZ1 is a tumor suppressor gene. The purpose of the present study was to investigate the inhibitory effect of RIZ1 gene therapy on the growth of SiHa cervical cancer cells and its synergism with paclitaxel. The expression levels of RIZ1 were examined by real-time PCR and western blotting before and after transfection of RIZ1. The effects of paclitaxel or pcDNA3.1(+)-RIZ1 alone or in combination, on the proliferation of SiHa cells were evaluated by MTT method. The inhibitory effect on the proliferation of SiHa cells was more significant in the pcDNA3.1(+)-RIZ1 combined with paclitaxel group than in the pcDNA3.1(+)-RIZ1 or paclitaxel groups (P<0.05). The expression level of RIZ1 in SiHa cells increased after treatment with paclitaxel, which indicated a synergism between them. RIZ1 gene therapy combined with paclitaxel showed stronger cell inhibition than paclitaxel alone, which indicated a synergism between them.
authors.affiliation: Department of Gynecologic Oncology, The Tumor Hospital of Harbin Medical University, Heilongjiang, China.
authors.forename: H Y
authors.initials: HY
authors.lastname: Cheng
authors.affiliation: Department of Gynecologic Oncology, The Red Flag Hospital of Mudanjiang Medical School, Heilongjiang, China.
authors.forename: T
authors.initials: T
authors.lastname: Zhang
authors.affiliation: Department of Gynecologic Oncology, The Traditional Chinese and Western Medicine Hospital of Fengtai District, Beijing, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Qu
authors.affiliation: Department of Gynecologic Oncology, The Tumor Hospital of Harbin Medical University, Heilongjiang, China.
authors.forename: W J
authors.initials: WJ
authors.lastname: Shi
authors.affiliation: Department of Gynecologic Oncology, The Tumor Hospital of Harbin Medical University, Heilongjiang, China.
authors.forename: G
authors.initials: G
authors.lastname: Lou
authors.affiliation: Department of Gynecologic Oncology, The Tumor Hospital of Harbin Medical University, Heilongjiang, China.
authors.forename: Y X
authors.initials: YX
authors.lastname: Liu
authors.affiliation: Department of Gynecologic Oncology, The Tumor Hospital of Harbin Medical University, Heilongjiang, China.
authors.forename: Y Y
authors.initials: YY
authors.lastname: Zhang
authors.affiliation: Department of Gynecologic Oncology, The Tumor Hospital of Harbin Medical University, Heilongjiang, China.
authors.forename: L
authors.initials: L
authors.lastname: Cheng
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D003131:Combined Modality Therapy; D004268:DNA-Binding Proteins / Q000096:biosynthesis / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy; D011495:Histone-Lysine N-Methyltransferase / Q000096:biosynthesis / Q000235:genetics*; D006801:Humans; D009687:Nuclear Proteins / Q000096:biosynthesis / Q000235:genetics*; D017239:Paclitaxel / Q000494:pharmacology*; D014157:Transcription Factors / Q000096:biosynthesis / Q000235:genetics*; D002583:Uterine Cervical Neoplasms / Q000628:therapy*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D014157:Transcription Factors; D011495:Histone-Lysine N-Methyltransferase; C093563:PRDM2 protein, human; D017239:Paclitaxel